BioSpace News Archive

Policy

MRNA-4157/V940 in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the EMA for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

Moderna, Inc. and Merck announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, has been granted Priority Medicines scheme designation by the European Medicines Agency for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.

April 6, 2023
·
49 min read
Drug Development

Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease (“COPD”)

Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.

April 6, 2023
·
5 min read